This growth is primarily driven by the increasing prevalence of cancer and cardiovascular diseases across the country. According to the American Cancer Society, the U.S. recorded approximately 1,958,310 new cancer cases in 2023, with 609,820 projected cancer-related deaths. The demand for nuclear medicine is further fueled by technological advancements and the growing need for precise diagnostic and treatment solutions.
Cardiovascular diseases remain the leading cause of death among most racial and ethnic groups in the U.S. As per a CDC report published in May 2023, around 805,000 Americans experience heart attacks annually, with 605,000 undergoing their first episode. To combat this, the U.S. government allocated nearly USD 239 billion annually between 2018 and 2019 for heart disease prevention and treatment, encompassing medication and healthcare services. Lifestyle factors such as alcohol consumption, unhealthy diets, and physical inactivity contribute significantly to the prevalence of cancer and heart diseases, thereby escalating the demand for nuclear medicine solutions.
The market is further driven by continuous technological innovation. Radiopharmaceuticals have transformed diagnostic and therapeutic practices in cardiology and oncology. Ongoing research highlights the efficacy of radioisotopes in treating a variety of health conditions, including cancer, thyroid disorders, respiratory ailments, bone issues, and gastrointestinal diseases. This scientific momentum is leading to the development of advanced nuclear medicine products for diagnostic and therapeutic use. For example, Siemens Healthineers introduced the Symbia Pro.specta in June 2022—an advanced SPECT and CT imaging system—which received both U.S. FDA clearance and CE mark approval for broad clinical application. Its features include automated workflows, SPECT motion correction for improved imaging, and a low-dose CT of up to 64 slices, setting it apart in the competitive landscape.
Order a free sample PDF of the U.S. Nuclear Medicine Market Intelligence Study, published by Grand View Research.
Key Market Trends & Insights
By Product: Diagnostic products held a dominant share, accounting for 71.2% of total revenue in 2023.
By End-use: Hospitals and clinics were the leading end-users in 2023.
By Application: The oncology segment led the market by application share in 2023.
Market Size & Forecast
2023 Market Size: USD 5.1 billion
2030 Projected Market Size: USD 12.27 billion
CAGR (2024–2030): 12.6%
Key U.S. Nuclear Medicine Companies:
Eckert & Ziegler
Curium
GE Healthcare
Jubilant Life Sciences Ltd.
Bracco Imaging S.P.A
Nordion (Canada), Inc.
The Institute for Radioelements (IRE)
NTP Radioisotopes SOC Ltd.
Eczacibasi-Monrol
Lantheus Medical Imaging, Inc.
The Australian Nuclear Science and Technology Organization
Novartis (Advanced Accelerator Applications)
Siemens Healthineers AG
Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.